Obesity Today—May 5, 2026

This week’s Obesity update highlights clinical progress, pipeline expansion, access initiatives, regional care-model pilots, and R&D return concentration.

In this Newsletter

Dive deeper

💉 Boehringer’s survodutide hits Phase 3 obesity endpoints [1] [29 Apr 2026]

https://www.clinicaltrialsarena.com/news/boehringers-weight-loss-jab-as-good-as-wegovy-but-not-zepbound/
Context: Boehringer Ingelheim’s Phase 3 SYNCHRONIZE-1 trial studied survodutide in adults with obesity or overweight, without type 2 diabetes.
Key point: Survodutide met both co-primary endpoints, including average weight loss up to 16.6% at 76 weeks versus 3.2% with placebo.
Implication: May influence prescriber choice and payer reviews pending full data.

🧬 Zealand and Roche move petrelintide toward Phase 3 [2] [30 Apr 2026]

https://www.taiwannews.com.tw/news/6351117
Context: Zealand Pharma and Roche are advancing petrelintide, a once-weekly amylin analog for chronic weight management.
Key point: The partners plan to initiate Phase 3 trials in adults with obesity or overweight with weight-related comorbidities in H2 2026.
Implication: Signals pipeline investment and modality expansion.

📅 Amgen tests MariTide as monthly obesity option [3] [US • 01 May 2026]

https://www.biospace.com/business/amgen-positions-maritide-as-potential-best-monthly-obesity-drug
Context: Amgen launched Phase 3 MARITIME-Switch to study switching patients from weekly GLP-1 injections to MariTide.
Key point: Amgen is positioning MariTide as a monthly or less frequent injectable obesity therapy, with additional studies in diabetes, heart failure, and sleep apnea.
Implication: May influence prescriber choice and payer reviews pending full data.

📈 Eli Lilly raises 2026 outlook on GLP-1 demand [4] [US • 01 May 2026]

https://www.reuters.com/business/healthcare-pharmaceuticals/eli-lilly-raises-annual-profit-forecast-sustained-weight-loss-drug-demand-2026-04-30/
Context: Eli Lilly reported strong first-quarter sales for GLP-1 products including Mounjaro and Zepbound.
Key point: Lilly raised 2026 adjusted EPS guidance to $35.50–$37.00 and revenue guidance to $82bn–$85bn.
Implication: May influence payer reviews and competitive positioning as pricing pressure continues.

🌏 Novo Nordisk eyes Singapore as Asia-Pacific pilot hub [5] [Singapore • 02 May 2026]

https://www.straitstimes.com/business/companies-markets/ozempic-maker-sees-singapore-as-a-platform-to-pilot-treatments-for-diabetes-obesity
Context: Novo Nordisk moved its Asia-Pacific regional headquarters to Singapore in 2025.
Key point: The company sees Singapore as a platform to pilot diabetes and obesity treatments, telemedicine, public-private partnerships, and multidisciplinary care.
Implication: May expand screening, initiation, and follow-up at scale.

🔬 Deloitte flags GLP-1-driven R&D return concentration [6] [UK • 04 May 2026]

https://www.deloitte.com/uk/en/about/press-room/weight-loss-drugs-boom-drives-pharma-r-and-d-returns.html
Context: Deloitte’s annual R&D productivity analysis covered late-stage pipelines of the top 20 global biopharma companies.
Key point: Forecast R&D internal rate of return rose from 5.9% in 2024 to 7.0% in 2025, driven largely by GLP-1 obesity and diabetes assets.
Implication: Could inform investment priorities; interpretation depends on pipeline concentration and market access risk.

🏢 Lilly launches Employer Connect for obesity drug access [7] [US • 03 May 2026]

https://in.investing.com/news/company-news/lilly-launches-employer-platform-for-obesity-drug-access-93CH-5274355
Context: Eli Lilly launched Employer Connect to link employers with independent program administrators for obesity medication coverage.
Key point: The platform includes access pathways for Zepbound (tirzepatide) KwikPen, with network pharmacy availability at $449 across all doses.
Implication: May expand screening, initiation, and follow-up at scale.

Why it matters

Obesity pipelines are diversifying beyond weekly GLP-1 injections, including dual agonists, amylin analogs, and antibody-peptide formats.
Convenience is becoming a core differentiator, with Amgen emphasizing monthly or less frequent dosing for MariTide.
Lilly’s sales momentum shows demand remains strong, even as pricing and access negotiations intensify.
Singapore is emerging as a regional test bed for digital obesity and diabetes care models.
Deloitte’s analysis suggests GLP-1s are lifting sector returns while increasing exposure to concentrated pipeline risk.

📚 View the full Obesity archive on our research hub page

🚀 Accelerate your success. Contact us now

📂 Explore our case studies. See examples of our work.

💡 Read our insights. Learn from our latest reports and analysis

🎬 Watch on YouTube. Subscribe and never miss a video.

🧰 See our full range of services. Discover how we can help you.

FAQ

What did Boehringer Ingelheim report for survodutide?

Survodutide met both co-primary endpoints in Phase 3 SYNCHRONIZE-1, including weight loss up to 16.6% at 76 weeks versus 3.2% with placebo. Full data are expected at ADA 2026. [1]

What is petrelintide and who is developing it?

Petrelintide is Zealand Pharma’s amylin analog for chronic weight management, partnered with Roche. Phase 3 initiation is planned for H2 2026. [2]

How is Amgen positioning MariTide?

Amgen is testing MariTide as a monthly or less frequent obesity injection. MARITIME-Switch will evaluate switching patients from weekly GLP-1 therapy. [3]

Why did Eli Lilly raise its 2026 forecast?

Lilly cited strong demand for GLP-1 obesity and diabetes drugs, including Mounjaro and Zepbound, which helped offset pricing pressure. [4]

Why is Singapore important to Novo Nordisk?

Novo Nordisk sees Singapore as an Asia-Pacific hub for piloting diabetes and obesity care, telemedicine, partnerships, and multidisciplinary models. [5]

What risk did Deloitte identify around GLP-1s?

Deloitte said GLP-1s improved pharma R&D returns but created dependency on a small number of high-value assets, raising concentration risk. [6]

Entities / Keywords

Boehringer Ingelheim, BI, survodutide, SYNCHRONIZE-1, dual glucagon/GLP-1 receptor agonist
Novo Nordisk, Ozempic, Wegovy, semaglutide, Singapore, Asia-Pacific, telemedicine
Eli Lilly, Lilly, Zepbound, tirzepatide, Mounjaro, Foundayo, Employer Connect
Zealand Pharma, Roche, petrelintide, amylin analog
Amgen, MariTide, MARITIME-Switch, monthly obesity injection
Deloitte, pharma R&D returns, GLP-1, obesity pipeline, internal rate of return
Obesity, overweight, type 2 diabetes, chronic weight management, employer coverage